Department of Medicine, School of Medicine, University of Washington, Seattle.
Department of Health Services, School of Public Health, University of Washington, Seattle.
JAMA. 2021 Jan 12;325(2):138-145. doi: 10.1001/jama.2020.24326.
Therapeutic delivery of sodium nitrite during resuscitation improved survival in animal models of cardiac arrest, but efficacy has not been evaluated in clinical trials in humans.
To determine whether parenteral administration of sodium nitrite given by paramedics during resuscitation for out-of-hospital cardiac arrest improved survival to hospital admission.
DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, phase 2 randomized clinical trial including 1502 adults in King County, Washington, with out-of-hospital cardiac arrest from ventricular fibrillation or nonventricular fibrillation. Patients underwent resuscitation by paramedics and were enrolled between February 8, 2018, and August 19, 2019; follow-up and data abstraction were completed by December 31, 2019.
Eligible patients with out-of-hospital cardiac arrest were randomized (1:1:1) to receive 45 mg of sodium nitrite (n = 500), 60 mg of sodium nitrite (n = 498), or placebo (n = 499), which was given via bolus injection by the paramedics as soon as possible during active resuscitation.
The primary outcome was survival to hospital admission and was evaluated with 1-sided hypothesis testing. The secondary outcomes included out-of-hospital variables (rate of return of spontaneous circulation, rate of rearrest, and use of norepinephrine to support blood pressure) and in-hospital variables (survival to hospital discharge; neurological outcomes at hospital discharge; cumulative survival to 24 hours, 48 hours, and 72 hours; and number of days in the intensive care unit).
Among 1502 patients with out-of-hospital cardiac arrest who were randomized (mean age, 64 years [SD, 17 years]; 34% were women), 99% completed the trial. Overall, 205 patients (41%) in the 45 mg of sodium nitrite group and 212 patients (43%) in the 60 mg of sodium nitrite group compared with 218 patients (44%) in the placebo group survived to hospital admission; the mean difference for the 45-mg dose vs placebo was -2.9% (1-sided 95% CI, -8.0% to ∞; P = .82) and the mean difference for the 60-mg dose vs placebo was -1.3% (1-sided 95% CI, -6.5% to ∞; P = .66). None of the 7 prespecified secondary outcomes were significantly different, including survival to hospital discharge for 66 patients (13.2%) in the 45 mg of sodium nitrite group and 72 patients (14.5%) in the 60 mg of sodium nitrite group compared with 74 patients (14.9%) in the placebo group; the mean difference for the 45-mg dose vs placebo was -1.7% (2-sided 95% CI, -6.0% to 2.6%; P = .44) and the mean difference for the 60-mg dose vs placebo was -0.4% (2-sided 95% CI, -4.9% to 4.0%; P = .85).
Among patients with out-of-hospital cardiac arrest, administration of sodium nitrite, compared with placebo, did not significantly improve survival to hospital admission. These findings do not support the use of sodium nitrite during resuscitation from out-of-hospital cardiac arrest.
ClinicalTrials.gov Identifier: NCT03452917.
重要性:在动物心脏骤停模型中,亚硝酸钠的治疗性递药在复苏过程中提高了生存率,但在人类临床试验中尚未评估其疗效。
目的:确定在院外心脏骤停的复苏过程中,由护理人员给予静脉注射亚硝酸钠是否能提高患者存活至入院的几率。
设计、设置和参与者:这是一项在华盛顿州金县进行的双盲、安慰剂对照、2 期随机临床试验,纳入了 1502 名患有室颤或非室颤性院外心脏骤停的成年人。患者由护理人员进行复苏,并于 2018 年 2 月 8 日至 2019 年 8 月 19 日期间入组;随访和数据提取于 2019 年 12 月 31 日完成。
干预措施:符合条件的院外心脏骤停患者被随机分为(1:1:1)3 组,分别接受 45 mg 亚硝酸钠(n = 500)、60 mg 亚硝酸钠(n = 498)或安慰剂(n = 499),这些药物由护理人员尽快通过推注方式给予,在积极复苏过程中给予。
主要结果和措施:主要结局是存活至入院,并进行单侧假设检验。次要结局包括院外变量(自主循环恢复率、再次骤停率和使用去甲肾上腺素支持血压)和院内变量(存活至出院;出院时的神经学结局;24 小时、48 小时和 72 小时的累计生存率;以及入住重症监护病房的天数)。
结果:在 1502 名接受院外心脏骤停复苏的患者中(平均年龄 64 岁[标准差 17 岁];34%为女性),99%完成了试验。总体而言,45 mg 亚硝酸钠组有 205 名(41%)患者和 60 mg 亚硝酸钠组有 212 名(43%)患者存活至入院,而安慰剂组有 218 名(44%)患者存活至入院;45 mg 剂量与安慰剂的平均差异为-2.9%(单侧 95%CI,-8.0%至 ∞;P = .82),60 mg 剂量与安慰剂的平均差异为-1.3%(单侧 95%CI,-6.5%至 ∞;P = .66)。7 个预先指定的次要结局均无显著差异,包括 45 mg 亚硝酸钠组有 66 名(13.2%)患者和 60 mg 亚硝酸钠组有 72 名(14.5%)患者存活至出院,而安慰剂组有 74 名(14.9%)患者存活至出院;45 mg 剂量与安慰剂的平均差异为-1.7%(双侧 95%CI,-6.0%至 2.6%;P = .44),60 mg 剂量与安慰剂的平均差异为-0.4%(双侧 95%CI,-4.9%至 4.0%;P = .85)。
结论和相关性:在院外心脏骤停患者中,与安慰剂相比,给予亚硝酸钠并未显著提高存活至入院的几率。这些发现不支持在院外心脏骤停复苏期间使用亚硝酸钠。
试验注册:ClinicalTrials.gov 标识符:NCT03452917。